Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.
Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.
复制标题
多发性硬化症的静脉免疫球蛋白治疗：从泰勒病毒模型中的髓鞘再生到随机、双盲、安慰剂对照临床试验的进展。
DOI：
10.1136/jnnp.57.suppl.11
复制
发表时间：
1994
期刊：
影响因子：
--
通讯作者：
Rodriguez,M
中科院分区：
文献类型：
--
作者：
Noseworthy,JH;O'Brien,PC;vanEngelen,BG;Rodriguez,M
没有发现逆转多发性硬化症（MS）患者长期神经功能障碍的治疗方法。在MS动物模型中的观察显示，针对CNS组分的免疫球蛋白促进少突胶质细胞增殖和新髓鞘合成。在人类外周和中枢神经系统的炎性脱髓鞘疾病中的初步研究表明，多克隆人免疫球蛋白（IVIg）的重复静脉内给药有时会导致临床改善。设计了一项随机、安慰剂对照、双盲临床试验，以检验IVIg重复给药将导致明显不可逆丧失的神经功能（虚弱）恢复到有意义程度的假设。共有76例MS患者将参与本研究。这些患者出现了固定的、明显的永久性虚弱，在过去的4到18个月里没有改善。如果有效，IVIg给药可能通过增强炎症脱髓鞘病变进展中髓鞘修复的潜力，使大部分患有活动性疾病的MS患者受益。
No treatment has been found which reverses long-standing neurological dysfunction in patients with multiple sclerosis (MS). Observations in animal models of MS show that immunoglobulins directed against CNS components promote oligodendroglial proliferation and new myelin synthesis. Preliminary studies in inflammatory-demyelinating diseases of the human peripheral and central nervous system suggest that the repeated intravenous administration of polyclonal human immunoglobulin (IVIg) is sometimes followed by clinical improvement. A randomised, placebo-controlled, double-blind, clinical trial was designed to test the hypothesis that repeated administration of IVIg will result in a meaningful degree of recovery of apparently irreversibly lost neurological function (weakness). A total of 76 patients with MS will participate in the study. These patients had developed a fixed, apparently permanent weakness that had not improved in the preceding four to 18 months. If effective, IVIg administration may benefit the large proportion of patients with MS who have active disease by enhancing the potential for myelin repair in the evolution of the inflammatory-demyelinating lesion.